M&A / Deals Eli Lilly to buy trio of vaccine developers in $3.8bn outlay Pharmaceutical TechnologyVia the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.Infectious DiseaseRead full story pharminent May 26, 2026 (Last updated: May 26, 2026) Pharmaceutical Technology Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus. Infectious Disease Read full story Post navigation Previous: Arthrosi drug trial in gout delivers for new owner SobiNext: Early data for heart drug affirm Lilly’s billion-dollar bet on Verve Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
